# GLEAM (NCT03816163)

> A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03816163
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Astellas Pharma Global Development, Inc.
- Conditions: Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma
- Interventions: zolbetuximab; nab-paclitaxel; gemcitabine
- Enrollment: 393
- Primary outcome: Dose Limiting Toxicities (DLT) - (safety lead in)
- Primary outcome: Overall Survival (OS)
- Primary outcome: Safety assessed by Adverse Events (AEs)
- Primary outcome: Safety assessed by incidence of serious adverse events (SAE)
- Primary outcome: Safety assessed by incidence of treatment emergent adverse events (TEAE)
- Primary outcome: Number of participants with laboratory value abnormalities and/or adverse events (AEs)
- Primary outcome: Number of participants with vital sign abnormalities and /or adverse events (AEs)
- Primary outcome: Number of participants with electrocardiograms (ECG) abnormalities and or adverse events
- Primary outcome: Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse events

## Indexed commentary on GLEAM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 17
- YouTube: 4
- Podcasts: 2
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=gleam-nct03816163

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03816163", "email": "<work email>"}; the inbox owner confirms by the emailed link.